Nirmatrelvir–ritonavir for the treatment of COVID‐19 patients: A systematic review and meta‐analysis-Reference-Cited by-同舟云学术

Nirmatrelvir–ritonavir for the treatment of COVID‐19 patients: A systematic review and meta‐analysis

Published:2023-01-12 Issue:2 Volume:95 Page:
ISSN:0146-6615
Container-title:Journal of Medical Virology
language:en
Short-container-title:Journal of Medical Virology

Author:

Cheema Huzaifa A.¹,Jafar Uzair¹^ORCID,Sohail Aruba²,Shahid Abia¹,Sahra Syeda³,Ehsan Muhammad¹,Athar Farwa¹,Shah Jaffer⁴,Sah Ranjit⁵

Affiliation:

1. Division of Infectious Diseases, Department of Medicine King Edward Medical University Lahore Pakistan

2. Department of Medicine Dow University of Health Sciences Karachi Pakistan

3. Department of Infectious Diseases University of Oklahoma Health Sciences Center Oklahoma City Oklahoma USA

4. New York State Department of Health Albany New York USA

5. Tribhuvan University Teaching Hospital Institute of Medicine Kathmandu Nepal

Publisher

Wiley

Subject

Infectious Diseases,Virology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jmv.28471

Reference19 articles.

1. Efficacy and safety of molnupiravir for COVID-19 patients

2. U.S. Food and Drug Administration (FDA). Coronavirus (COVID‐19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID‐19. Food and Drug Administration. Published 2021. Accessed October 18 2022.https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19

3. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study

4. Real‐world effectiveness of nirmatrelvir/ritonavir in preventing hospitalization among patients with COVID‐19 at high risk for severe disease in the United States: a nationwide population‐based cohort study;Zhou X;medRxiv,2022

5. Oral Nirmatrelvir and Ritonavir in Nonhospitalized Vaccinated Patients With Coronavirus Disease 2019

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of COVID-19 Oral antivirals in hospitalised oldest-old with high morbidity burden: a target trial emulation study;Age and Ageing;2024-08

2. Nirmatrelvir/Ritonavir Regimen for Mild/Moderately Severe COVID-19: A Rapid Review With Meta-Analysis and Trial Sequential Analysis;The Annals of Family Medicine;2024-07

3. Effectiveness and safety of azvudine in COVID-19: A systematic review and meta-analysis;PLOS ONE;2024-06-13

4. Molnupiravir for the treatment of COVID-19 outpatients: An updated meta-analysis;Journal of Microbiology, Immunology and Infection;2024-06

5. Safety of RNA-Dependent RNA Polymerase Inhibitors, Molnupiravir and VV116, for Oral Treatment of COVID-19: A Meta-Analysis;IRAN J MED SCI;2024